StockMarketWire.com - Collagen Solutions said it had achieved successful results from an eight-year extension clinical study of 15 patients who received its knee implants.
The positive results had allowed Collagen Solutions to submit an initial submission for a CE Mark, the company said.
Quantitative 3D MRI analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage.
Improvement in patient clinical symptoms, including pain, function and activity level after treatment, was sustained over the eight-year period.
'This compelling data is a significant achievement in the decades-long effort by clinicians and scientists to develop a cost-effective and clinically effective treatment for these types of cartilage defects,' chief executive Jamal Rushdy said.
'We have illustrated the commercial opportunities with the announcement of an agreement with our South Korean partner in December last year.'
'We look forward to announcing further key milestones including the granting of the CE Mark over the next few months.'
At 1:43pm: [LON:COS] Collagen Solutions Plc share price was +0.5p at 3.2p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.